Table 2.
Assessment of clinical outcomes
| Pt | IL21 | Leukemia WT1 expression |
Leukemia burden at time of CTL infusions |
CTL persistence (days) |
Outcome* | GVHD after CTL? |
Additional treatment after CTL? |
Alive/ Dead |
|---|---|---|---|---|---|---|---|---|
| 1 | No | Yes** | Present | 14 | Progressed while receiving CTL |
NO | YES | dead |
| 2 | No | Yes** | Present | 14 | Relapsed while receiving CTL |
NO | YES | dead |
| 6 | No | Unavailable | Absent | 14 | CR/chronic GVHD 4.9 years after CTL, 6 years post HCT |
YES (pre- existing) |
NO | alive |
| 10 | No | Yes** | Present | 14 | Relapse while receiving CTL |
NO | YES | dead |
| 15 | No | Yes** | Present | 14 | Progressed after responding to 1st CTL infusion |
NO | NO | dead |
| 17 | No | Yes** | Absent | 7 | Relapsed D+132 post CTL |
NO | NO | dead |
| 20 | No | Yes** | Present | 5 | Progressed while receiving CTL |
NO | YES | dead |
| 21 | Yes | Yes*** | Absent | 430 | CR 30 months post 1st CTL, 35 months post HCT |
NO | NO | alive |
| 24 | Yes | Yes*** | Absent | 430+ | CR 28 months post 1st CTL, 33 months post HCT |
NO | NO | alive |
| 27 | Yes | Yes** | Present | 430+ | CR 19 months post 1st CTL, 22 months post HCT |
NO | NO | alive |
| 28 | Yes | Yes*** | Absent | 230+ | CR 18 months post 1st CTL, 38 months post HCT |
NO | NO | alive |
*
As of 08/15/2012
**
Assessed by PCR
***
Assessed by immunohistochemistry